Vicarious Surgical, Inc. (NYSE:RBOT) Q4 2022 Earnings Conference Call February 13, 2023 4:30 PM ET

Company Participants

Kaitlyn Brosco - IR

Adam Sachs - Co-Founder, CEO, President & Director

William Kelly - CFO & Treasurer

Conference Call Participants

Ryan Zimmerman - BTIG

Eric Anderson - Cowen and Company

Adam Maeder - Piper Sandler & Co.

Kyle Rose - Canaccord Genuity

Operator

Good afternoon, and welcome to the Vicarious Surgical's Fourth Quarter 2022 Earnings Conference Call. My name is Tia, and I will be your operator for today's call. [Operator Instructions].

I would now like to turn the call over to Kaitlyn Brosco with Vicarious Surgical for a few introductory comments. Please proceed.

Kaitlyn Brosco

Thank you, Tia, and thank you all for participating in today's call. Earlier today, Vicarious Surgical released financial results for the 3 months and full year ended December 31, 2022. A copy of the press release is available on the company's website.

Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements.

All forward-looking statements, including, without limitation, those relating to our operating trends and future financial performance, expense management, market opportunity and commercialization are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements.

For a list and description of the risks and uncertainties associated with our business, please refer to the risk factors set forth in our Securities and Exchange Commission filings, including our most recent Form 10-K and Form 10-Q. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, February 13, 2023. Vicarious Surgical disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise.

With that, I'll turn the call over to Adam Sachs, Chief Executive Officer.

Adam Sachs

Thanks, Kate. Good afternoon, everyone, and thank you for joining our full year 2022 earnings call. In 2022, our first full year as a public company, I'm pleased to share that we made significant progress toward our objectives of finalizing the Vicarious Surgical system, preparing for regulatory review and expanding our surgeon and health system relationships as part of early commercial readiness. I'll start by reviewing our key accomplishments before discussing our early progress and outlook for 2023.